News
![Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?: https://www.marketbeat.com/logos/articles/med_20240421181833_charts-lly.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXg4YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd8c2ba6e5323ef28e176a02577fb376fb8e136e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240421181833_charts-lly.jpg?locale=us)
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V (NYSE: NVO) with its Semaglutide medications
![Akebia Therapeutics Surges on FDA Approval for Anemia Treatment: https://www.marketbeat.com/logos/articles/med_20240331142316_untitledchart-akd.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU5wYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--56154e370edb0db76935de2e3b68d3731ccb9fe0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240331142316_untitledchart-akd.jpg?locale=us)
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The
![5 Stocks with Unusually Large Short Interest: https://www.marketbeat.com/logos/articles/med_20240307141801_5-stocks-with-unusually-large-short-interest.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0ZPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--93cbfada310662b5c1c47556f7d5a9cef0a68dd1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240307141801_5-stocks-with-unusually-large-short-interest.jpg?locale=us)
5 Stocks with Unusually Large Short Interest
With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again
![Novavax’s dispute resolution and upcoming earnings call: https://www.marketbeat.com/logos/articles/med_20240222142457_novavaxs-dispute-resolution-and-upcoming-earnings.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0k5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--03dff2262d97f7d522f9492197704d486ee848e9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240222142457_novavaxs-dispute-resolution-and-upcoming-earnings.jpg?locale=us)
Novavax’s dispute resolution and upcoming earnings call
Novavax (NASDAQ: NVAX) is a biotechnology pioneer dedicated to developing innovative vaccines against serious infectious diseases. Their unique approach utilizes protein-based technology, an
![Analysts see over 50% gains in these 2 mid-cap biotech stocks: https://www.marketbeat.com/logos/articles/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3N5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48eba343d55323cc51dbade828ae7ba56a5f4cb6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg?locale=us)
Analysts see over 50% gains in these 2 mid-cap biotech stocks
2024 is shaping up to be a pivotal year for the biotechnology industry.
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way
![3 mid-caps under $20 that Wall Street loves: https://www.marketbeat.com/logos/articles/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVFUYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39856908cabc8ed79cba37b4b804a0473a9ba5e2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg?locale=us)
3 mid-caps under $20 that Wall Street loves
Just three trading weeks into the new year, a half dozen U.S. mid- or large-cap stocks are already up 20% or more.
Picking up where it left off last year, artificial intelligence (AI) data center
![2 biotechs with promising weight-loss drugs coming: https://www.marketbeat.com/logos/articles/med_20240114165130_chart-vktx2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFVNYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1beeff80657e84dcfd835627b1cd6ada42ca6d43/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240114165130_chart-vktx2.jpg?locale=us)
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. (NYSE: LLY) owned Mounjaro and Zepbound
![Voyager Therapeutics stock pops 30% on deal with Novartis: https://www.marketbeat.com/logos/articles/med_20240108080612_voyager-therapeutics-pops-30-on-gene-therapy-deal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWdFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6d8cf733f50b87149bec09f287b00c8d609fb8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240108080612_voyager-therapeutics-pops-30-on-gene-therapy-deal.jpg?locale=us)
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with
![2 gene-editing stocks reshaping hereditary disease treatments: https://www.marketbeat.com/logos/articles/med_20231231121858_chart-ntla.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkgrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8cf7f26c4d9caf0889b2db456211e7f76836263/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231231121858_chart-ntla.jpg?locale=us)
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a
![3 Dividend Champions with room for dividend growth: https://www.marketbeat.com/logos/articles/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0RUYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbf06ab40dff23457a16966fc5b6eb94f89bb974/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg?locale=us)
3 Dividend Champions with room for dividend growth
The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the
![2 Stocks That Doubled EPS Estimates and Flashing Buy Signals: https://www.marketbeat.com/logos/articles/med_20230827122241_chart-edr2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmVFYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b90155622a620fcdbed67112976eb3db92cedf09/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230827122241_chart-edr2.jpg?locale=us)
2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with upcoming catalysts to watch. These
![Saturn Oil & Gas Inc. meldet Finanz- und Betriebsergebnisse für das zweite Quartal 2023 mit Rekordzahlen bei der Quartalsproduktion und dem bereinigten Cashflow: https://www.irw-press.at/prcom/images/messages/2023/71644/Saturn_081423_DEPRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTl5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a5935e64bff34fc0331513331ace23ff55270f2a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_081423_DEPRcom.003.png?locale=us)
Saturn Oil & Gas Inc. meldet Finanz- und Betriebsergebnisse für das zweite Quartal 2023 mit Rekordzahlen bei der Quartalsproduktion und dem bereinigten Cashflow
CALGARY, ALBERTA - 14. August 2023 / IRW-Press / Saturn Oil & Gas Inc. (TSX: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush: https://www.marketbeat.com/logos/articles/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXRZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b9f83eb09fecce9f51f50355f2bfdb6f72cf87cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg?locale=us)
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
Shares of Eli Lilly & Co. (NYSE: LLY) closed 2.80% higher for the week ended July 21, a week after Lilly said it would buy Versanis, a privately held clinical-stage biopharmaceutical company
![MoonLake Immunotherapeutics Makes a Moonshot on Trials: https://www.marketbeat.com/logos/articles/med_20230627135359_chart-mltx.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0ErYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1cc03209bfa7ceffd01997226b0d66c205cde5a1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230627135359_chart-mltx.jpg?locale=us)
MoonLake Immunotherapeutics Makes a Moonshot on Trials
Clinical stage biotech MoonLake Immunotherapeutics AG (NASDAQ: MLTX) shares spiked 70% on positive phase two clinical trial results. The company specializes in nanobodies, fragments of antibodies
![ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials: https://www.marketbeat.com/logos/articles/med_20230625130240_chart-imgn2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOFU3YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--f735c6464d2acbda7d33d652f24106d39bfad031/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230625130240_chart-imgn2.jpg?locale=us)
ImmunoGen Stock Continues to Defy Gravity on Phase 2 Trials
ImmunoGen Inc. (NASDAQ: IMGN) is a commercial-stage biotechnology company leading in antibody-drug conjugates (ADC). ADCs are like heat-seeking missiles that target and selectively deliver
![Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT: https://www.irw-press.at/prcom/images/messages/2023/70999/FITLIGHT_061523_DEPRcom.001.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVF5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--50f486fa803efa5e0e0e61eb3c214069d7373851/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/FITLIGHT_061523_DEPRcom.001.png?locale=us)
Clarence Seedorf und Khabib Nurmagomedov unterzeichnen mit ihrer SK Sports Holding eine weltweite Partnerschaftsvereinbarung mit FITLIGHT
FITLIGHT wird offizieller Technologiepartner von SK Sports Holding
MIAMI, FL / ACCESSWIRE / 15. Juni 2023 / SK Sports Holding, die im Jahr 2022 ihren ersten Seedorf Khabib Performance
![Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_DEPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlFRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ae4a6273fb7531fbea1a2791dc69f249162baac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_DEPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt
Calgary (Alberta), 16. Mai 2023 / IRW-Press / - Saturn Oil & Gas Inc. (TSX-V: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_ENPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmNRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfe1718b0f96e0cef29f22e19f3c3d1ee5d51975/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_ENPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production
CALGARY, ALBERTA – May 16, 2023 - Saturn Oil & Gas Inc. (TSXV: SOIL)(FSE: SMKA)(OTCQX: OILSF)(“Saturn” or the “Company”) is pleased to report its financial and operating results for the three
![Is Novavax Finally Turning Things Around?: https://www.marketbeat.com/logos/articles/med_20230514175918_chartt-nvax.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzBNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1adde23b9a3750d2f04deb8ca4ca0a45bf6b3fef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514175918_chartt-nvax.jpg?locale=us)
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza
![ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results: https://www.marketbeat.com/logos/articles/med_20230507142135_chartt-imgn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c1a764fe2e456cda77e41a5778e3a020ec701a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230507142135_chartt-imgn.jpg?locale=us)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for
![EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
EnWave Sells EU-GMP 10kW REV™ Machine to Pharmaceutical Cannabis Cultivator in Europe
Vancouver, B.C., June 29, 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
![EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
EnWave verkauft EU-GMP 10kW REV™ Maschine an Pharmazeutischen Cannabiszüchter in Europa
Vancouver, B.C., 29. Juni 2022 - EnWave Corporation (TSX-V:ENW | FSE:E4U) ("EnWave" oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab heute
![EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
EnWave verkauft 10kW Maschine an Fungaria Snack Ltd. für Obst- und Gemüseproduktion in Ungarn
Vancouver, B.C., 28. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave", oder das "Unternehmen" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/ ) gab
![EnWave Sells 10kW Machine to Fungaria Snack Ltd. for Fruit and Vegetable Production in Hungary](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
EnWave Sells 10kW Machine to Fungaria Snack Ltd. for Fruit and Vegetable Production in Hungary
Vancouver, B.C., June 28, 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) (“EnWave”, or the "Company" - https://www.commodity-tv.com/ondemand/companies/profil/enwave-corp/) announced today
![EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
EnWave verkauft dritte 10-kW-REV™-Maschine an Dairy Concepts IRL und erhöht damit weiter die Kapazität für die Produktion von lagerstabilen Molkereisnacks
Vancouver, B.C., 27. Juni 2022 - EnWave Corporation (TSX-V: ENW | FSE: E4U) ("EnWave") gab bekannt, dass Dairy Concepts IRL ("DCI"), ein aufstrebender Marktführer im Bereich innovativer